Roivant Shares Drop After Immunovant Trial Fails
Roivant Sciences (ROIV) shares fell in premarket trading after its subsidiary, Immunovant (IMVT), reported a failed proof-of-concept trial for IMVT-1402. The experimental therapy was being tested as a treatment for cutaneous lupus erythematosus, an autoimmune skin condition. The company cited 12-week data from the clinical trial that did not meet expectations, leading to disappointment among investors and triggering early trading losses. This setback could delay or alter Immunovant’s development plans for IMVT-1402, potentially affecting its pipeline progress and investor confidence in Roivant's strategy. The failure highlights risks inherent in drug development and may impact the broader biotech sector by reinforcing concerns over clinical trial outcomes.
